COPDEX-HIIT: High-intensity Interval Training in Patients With COPD: a Fidelity and Tolerability Study

Sponsor
Rigshospitalet, Denmark (Other)
Overall Status
Recruiting
CT.gov ID
NCT05273684
Collaborator
(none)
12
1
1
8
1.5

Study Details

Study Description

Brief Summary

Although high-intensity training (HIIT) is widely used in the rehabilitation of patients with chronic obstructive pulmonary disease (COPD), the optimal duration of intervals in terms of patient tolerability and fidelity is unknown.Thus, we will examine the fidelity and tolerability of the two most commonly used HIIT protocols, the classical so-called 4x4min vs. 10x1min in patients with moderate to severe COPD.

Condition or Disease Intervention/Treatment Phase
  • Other: High intensity interval training
N/A

Detailed Description

12 patients with severe to moderate COPD will be included in the study, where two different HIIT interventions will be compared with regards to fidelity and tolerability. Baseline measurements will be performed to assess fitness and cardiopulmonary health status for the included patients. The baseline measurements include a medical health interview and examination (blood pressure, heart rate, ECG), a maximal oxygen consumption (VO2max) test, lung function testing (dynamic spirometry, whole body plethysmography, diffusing capacity), and an assessment of body composition. The following two visits consist of two different HIIT protocols.

Each training session is evaluated by Borg Scale (5) and the Likert Scale (6), as well as time spent in with a heart rate above 85% of maximum. Each HIIT session is separated by at least a 3-day wash-out period.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
12 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
High-intensity Interval Training in Patients With COPD: a Fidelity and Tolerability Study
Actual Study Start Date :
Nov 1, 2021
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: 4*4 followed by 10*1 or 10*1 followed by 4*4

Following baseline measurements, participants are allocated to the random sequence, by which they will complete the two HIIT protocols ⟨http://www.randomization.com⟩ and based on this, patients are randomized to a specific testing sequence.

Other: High intensity interval training
Participants will undergo 4x4 and 1x10 minutes of interval training on two separate days.

Outcome Measures

Primary Outcome Measures

  1. Exercise feasibility: Relative dose intensity (RDI) of exercise [1 week]

    RDI (%) of exercise, defined as prescribed exercise dose / performed exercise dose x 100 Evaluated with a Red-Amber-Green system: Green: If ≥85% of the training is completed Amber: If 50-85% of the training is completed Red: If ≤ 50% of the training is completed

  2. Exercise feasibility: Exercise sessions requiring dose modifications [1 week]

    Incidence of exercise sessions requiring dose modifications, defined as any deviation from the prescribed exercise.

  3. Exercise tolerability: Subjective rating of the exercise session [1 week]

    Tolerability is measured with a 10-point Likert scale, where the participants evaluate the two HIIT protocols. They will anser two quesitens: How tolerable was todays traning? How much did you enjoy todays training? Where 1 means not at all, and 10 means alot. The Likert scale is scored as: Red: 1-2 Amber: 3-4 Green: +5

  4. Exercise feasibility: Exercise sessions attendance rate [1 week]

    Exercise sessions attendance rate (%), defined as number of attended exercise sessions / number of prescribed exercise sessions x 100

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Men and women

  • 18-80 years

  • Moderate to severe COPD(GOLD stage II to III)

Exclusion Criteria:
  • Known ischaemic heart disease

  • Known heart failure

  • Previous or current coronavirus disease 2019 (COVID-19)

  • Dementia or other severe neurological disease

  • Known vascular

  • Symptoms of disease within 2 weeks prior to the study

  • Pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rigshospitalet Copenhagen Denmark 2100

Sponsors and Collaborators

  • Rigshospitalet, Denmark

Investigators

  • Principal Investigator: Ronan Berg, MD, Rigshospitalet, Denmark

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ronan Berg, MD, DMSc, Associate professor, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT05273684
Other Study ID Numbers:
  • CFAS_2021_1
First Posted:
Mar 10, 2022
Last Update Posted:
Jun 6, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ronan Berg, MD, DMSc, Associate professor, Rigshospitalet, Denmark

Study Results

No Results Posted as of Jun 6, 2022